Patient-focused Development of Biopharmaceutical Products
Language: English
Published by Springer, 2025
- Hardcover
- New

Condition: New
£ 57.33
Quantity: 2 available
Add to basketItem description from seller
This open access book builds the case for the business motivation, techniques, and approaches to use in development of a medicinal product for human therapy, whether delivered via an oral dose form ("pill" or solution) or a delivery system (device). It shares the growing demands by patients and caregivers, as well as regulators, for designs which are most easily understood and usable, and which can ensure the medication can be consistently delivered and will, therefore, allow best outcomes. The book weaves skills in "human-centered design" into the design of medicinal delivery systems. It would be a reference for those in academia studying pharmacokinetics, formulation or product design and development, as well as those in the development of biopharmaceutical therapies. This is an open access book. Sprache: Englisch Gewicht in Gramm: 349.
Seller Inventory # IB-4482009
- Title
- Patient-focused Development of Biopharmaceutical Products
- Publisher
- Springer
- Publication year
- 2025
- Condition
- Neu
- Binding
- Gebundene Ausgabe
- Language
- English
- ISBN 10
- 3031982525
- ISBN 13
- 9783031982521
- Item weight
- 349 grams
This open access book builds the case for the business motivation, techniques, and approaches to use in development of a medicinal product for human therapy, whether delivered via an oral dose form (“pill” or solution) or a delivery system (device). It shares the growing demands by patients and caregivers, as well as regulators, for designs which are most easily understood and usable, and which can ensure the medication can be consistently delivered and will, therefore, allow best outcomes. The book weaves skills in “human-centered design” into the design of medicinal delivery systems. It would be a reference for those in academia studying pharmacokinetics, formulation or product design and development, as well as those in the development of biopharmaceutical therapies.
This is an open access book.
"Synopsis" may belong to another edition of this title.
About the Author
Robert Nesbitt is Senior Director, Landscaping & Platform Definition in AbbVie’s Combination Product Development group. Prior to that, he was Director, Human-Centered Design & Human Factors, and led the team that drove user needs assessment and usability validation for AbbVie Combination Products.He was co-editor of Development of Biopharmaceutical Drug-Device Products, a book for pharmaceutical development professionals on drug product formulation, development and the delivery systems which are required to deliver them. This 800-page book was published by Springer as Volume 35 of AAPS’ “Advances in the Pharmaceutical Sciences” series (2020).
He joined AbbVie in January-2015, after 16 years at Eli Lilly and Company, where as Director of Advanced Development and Research, he built patient-centered design into early concept design and development of new Lilly delivery devices. His work drove the design of nine (9) different Lilly delivery devices in use today globally – his team led the design of the device Lilly uses for Trulicity, Emgality, Taltz, Mounjaro and Zepbound. After retirement from Lilly (2015), he was called back and recognized as a “Top Innovator” for his leadership in driving the patient-centered design of the auto-injector used for three Lilly therapeutics.
Ramakrishna (“Krishna”) Venugopalan is currently the Co-Founder and CEO of Continuity Biosciences, LLC, a biotechnology company established with the mission of revolutionizing therapeutic delivery. At Continuity, proprietary platform technologies are leveraged to develop next-generation drug delivery systems aimed at addressing bioavailability challenges and mitigating systemic toxicity, particularly in oncology and metabolic diseases.
Prior to founding Continuity, Krishna led AbbVie’s combination product, drug delivery, and sterile packaging development organization, integrating medical technology with biotechnology within AbbVie’s pipeline. He played a central role in the launch of impactful therapies, including Skyrizi®—an IL-23 inhibitor widely used to treat autoimmune diseases—and Vyalev™, a continuous subcutaneous infusion therapy providing enhanced symptom control for patients with advanced Parkinson’s disease.
Before his tenure at AbbVie, he held leadership positions at Johnson & Johnson focused on drug-device combination development, M&A integration, and external partnerships. In 2016, he received the Johnson Medal for co-developing a continuous glucose monitor integrated insulin pump; an effort which complemented his research and development focus on closed-loop insulin delivery systems for type 1 diabetes.
Wolfgang Fraunhofer is Senior Director, CMC Strategy and Portfolio Leadership, in Development Sciences, R&D at AbbVie. Previously, he led teams in NCE Analytical R&D, Combination Product Development, NBE Formulation Development and NCE/NBE Pharmaceutics/Preformulation.
He began his pharmaceutical development career at BASF/Knoll, first while completing his doctoral research on protein aggregate characterization, and later as member of the team developing formulations and product presentations for adalimumab, one of the most widely used monoclonal antibodies that has transformed immunology treatments. His pharmaceutical expertise has been deployed in the development of various pharmaceutical excipients as well as the development of lyophilized and liquid new biological entities (NBEs). Upon Abbott Labs purchase of BASF’s Knoll Division, Dr. Fraunhofer worked on Drug Product scale up and transfer to manufacturing sites at locations in Germany as well as Puerto Rico, supporting the development of manufacturing quality criteria and training of the operators in the manufacture and final GMP release of adalimumab (Humira®).
"About the title" may belong to another edition of this title.
Shipping rates from Germany to U.S.A.
| Item | 10 to 12 business days | 8 to 10 business days |
|---|---|---|
| First item | £ 41.54 | £ 62.44 |
Payment methods
- Check
Specialty
BuchRight of withdrawal
If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
Information regarding the right of withdrawal
Statutory right to withdraw
You have the right to withdraw from this contract within 14 days without giving any reason.
The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.
To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.
To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.
Effects of withdrawal
If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to Home-set, Mannheim, Germany, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of withdrawal
The right of withdrawal does not apply to:
- The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
- The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.